Ocular Axial Growth During Childhood: Mechanisms, Clinical Implications, and Management Strategies

Abstract

Ocular axial growth during childhood is a pivotal process influencing the refractive status and long-term visual outcomes in pediatric populations. Aberrations in this growth trajectory are central to the pathogenesis of myopia, a condition with rising global prevalence and significant public health implications. This review synthesizes current evidence on epidemiology, pathophysiological mechanisms, risk factors, clinical features, diagnostic approaches, and management strategies for abnormal ocular axial elongation. Special emphasis is placed on recent advances, including pharmacologic and optical interventions, and guideline-driven recommendations, aiming to equip clinicians with a comprehensive understanding for optimal patient care.

Introduction

The regulation of ocular axial length during childhood forms the cornerstone of emmetropization, the process by which the eye achieves near-zero refractive error. Disruption of this finely tuned mechanism, particularly excessive axial elongation, is a primary driver of myopia and its associated complications. Given the increasing prevalence of childhood myopia worldwide, understanding the determinants of ocular axial growth and evidence-based approaches to its management has become a clinical imperative. This article explores the multifactorial influences on axial length development, clinical manifestations of aberrant growth, and contemporary management paradigms, offering a critical synthesis for healthcare professionals.

Epidemiology / Disease Burden

Myopia, primarily attributable to increased ocular axial length, has reached epidemic proportions, especially in East Asia where prevalence rates among school-aged children approach 80%. Globally, projections estimate that by 2050, nearly 50% of the world\'s population may be affected by myopia, with a substantial subset developing high myopia (>-6.0 D), which confers increased risk for sight-threatening complications. The burden extends beyond refractive correction, encompassing societal, educational, and economic impacts, and highlighting the necessity for early identification and intervention in children at risk for excessive axial elongation.

Pathophysiology

Axial growth of the eye is tightly regulated by genetic and environmental factors. The sclera, primarily responsible for ocular elongation, undergoes active remodeling in response to visual stimuli. Retinal defocus, particularly hyperopic defocus, initiates a signaling cascade involving neurotransmitters such as dopamine, leading to altered extracellular matrix composition and scleral thinning. Disruption of normal emmetropization, whether due to genetic predisposition or environmental factors such as increased near work and limited outdoor activity, results in excessive axial elongation and myopia progression. The role of choroidal thickness and biomechanical properties of the sclera are areas of ongoing research, with implications for targeted therapies.

Risk Factors

Several modifiable and non-modifiable risk factors contribute to abnormal ocular axial growth. Parental myopia is a strong predictor, with children of two myopic parents exhibiting the highest risk. Environmental determinants include intensive educational demands, excessive near work, and insufficient exposure to natural outdoor light. Recent studies underscore the protective effect of outdoor activity, possibly mediated by increased retinal dopamine release in response to higher light intensity. Additional risk factors encompass early onset of myopia, rapid progression rates, and certain ethnic backgrounds, particularly East Asian populations.

Clinical Features

Excessive ocular axial growth manifests primarily as progressive myopia in children. Clinical hallmarks include increasing negative spherical equivalent refractive error, elongation of the axial length as measured by optical biometry, and, in advanced cases, fundoscopic changes such as tessellated fundus or peripapillary atrophy. Early identification of rapid axial elongation is crucial, as children with annual axial growth exceeding 0.2 mm are at heightened risk for high myopia and its sequelae, including retinal detachment and myopic maculopathy in later life. Subtle symptoms, such as frequent prescription changes or complaints of blurred distance vision, warrant prompt evaluation.

Diagnosis

Accurate assessment of ocular axial length is fundamental for diagnosing and monitoring abnormal growth. Non-contact optical biometry (e.g., IOLMaster, Lenstar) offers high precision and reproducibility. Comprehensive refractive assessment, cycloplegic refraction, and fundus examination are essential adjuncts. Serial measurements of axial length, in conjunction with refractive error progression, enable risk stratification and inform management decisions. Ancillary investigations, such as corneal topography and optical coherence tomography, may provide additional insights into ocular structural changes associated with axial elongation.

Treatment & Management

Management strategies for abnormal ocular axial growth focus on slowing myopia progression and mitigating long-term risks. Evidence-based interventions include pharmacologic therapy with low-dose atropine (0.01-0.05%), which has demonstrated significant efficacy in reducing axial elongation with minimal side effects. Optical interventions, such as orthokeratology lenses and multifocal soft contact lenses, have also shown benefit, likely by reducing peripheral retinal hyperopic defocus. Environmental modifications, including increasing outdoor activity and optimizing near work habits, are recommended adjuncts. Regular monitoring of axial length and refractive error progression is imperative to tailor interventions.

Recent Advances / Emerging Therapies

Recent years have seen the emergence of novel technologies and pharmacologic agents targeting the mechanisms underlying axial elongation. MiSight 1 day contact lenses, approved by regulatory authorities, employ a dual-focus design to slow myopia progression. Research into higher-concentration atropine and novel compounds such as 7-methylxanthine, as well as scleral cross-linking procedures, offers promising avenues for future intervention. Advances in genetic risk profiling and biomarker discovery may enable personalized risk assessment and targeted prevention strategies.

Guideline Recommendations

International clinical practice guidelines emphasize early risk identification, comprehensive refractive and axial length assessment, and evidence-based interventions for children demonstrating myopia progression or rapid axial elongation. Consensus statements from professional bodies recommend low-dose atropine as first-line pharmacologic therapy, with optical interventions considered in appropriate cases. Annual or biannual monitoring of axial length is advised for at-risk children. Multidisciplinary collaboration, including parental education and public health initiatives to promote outdoor activity, forms an integral component of guideline-based care.

Conclusion

Ocular axial growth during childhood is a critical determinant of lifelong visual health. Understanding the complex interplay of genetic, environmental, and biomechanical factors that govern axial elongation enables clinicians to identify high-risk children and implement effective, evidence-based interventions. Continued research into the molecular mechanisms and innovative therapies holds promise for reducing the global burden of myopia and its complications. Proactive, guideline-driven management of ocular axial growth remains essential for optimizing visual outcomes in pediatric populations.